Thyroid Eye Disease, Elegrobart, Phase 3, VRDN-003

Thyroid Eye Disease, Elegrobart, Phase 3, VRDN-003

Elegrobart's Zero Hearing Loss and Subcutaneous Convenience Rewrite the Playbook for Thyroid Eye Disease

Phase 3 REVEAL-1 data establishes a differentiated safety profile for Elegrobart, utilizing an extended half-life YTE mutation and Q8W dosing to bypass the severe sensorineural hearing loss characteristic of current intravenous IGF-1R therapies. See Disclaimer below * Thyroid Eye Disease is a disfiguring, potentially blinding autoimmune condition marked by severe ocular